Intuitive Surgical, Inc. (ISRG) SEC Filings & Earnings Calls

China NHSA Pricing Framework

“Beginning in the fourth quarter of 2026, we expect to implement price reductions on instruments sold in China in response to the continued rollout of the NHSA unified national pricing framework. We expect these price reductions to reduce instruments and accessories revenue per procedure.” · word for word

China Governance Campaign

“In the third quarter of 2026, the competitive dynamics in China, various measures related to industrial policy, and the effects of this campaign contributed to fewer systems being placed in China than we anticipated.” · word for word

Tariff Uncertainty

“Future changes to tariff rates and the imposition of new tariffs by the U.S. and/or other countries could result in a material impact on our results of operations.” · word for word

Semiconductor Supply Constraints

“We continue to experience extended delivery lead times and price volatility for certain semiconductor components, including memory and printed circuit boards, driven by industry demand for data processing and storage applications.” · word for word

U.S. Procedure Growth Deceleration

“U.S. da Vinci procedures grew approximately 10% for the three months ended September 30, 2026, compared to approximately 16% for the three months ended September 30, 2025.” · word for word

Tariff exposure could impact gross margin; estimated 0.9% of revenue headwind in FY26.

“Non-GAAP gross profit margin range includes an estimated impact from tariffs of 0.9% of revenue. Additional tariffs could be material.”

Antitrust litigation settlement for $450M, though resolved, required significant cash outflow.

“Settlement of previously disclosed antitrust class action litigation for $450 million pre-tax.”

Share repurchase of $2.94B in one quarter reduces cash reserves significantly.

“Cash, cash equivalents, and investments decreased by $1.83B during the quarter, primarily driven by share repurchases.”

China Market Headwinds

“In the second quarter of 2026, the competitive dynamics in China, various measures related to industrial policy, and the effects of this campaign contributed to fewer systems being placed in China than we anticipated.” · word for word

Tariff Cost Exposure

“Future changes to tariff rates and the imposition of new tariffs by the U.S. and/or other countries could result in a material impact to our results of operations.” · word for word

Hospital Capital Spending Constraints

“We continue to see some customers challenged by lower public funding of healthcare in certain geographic markets and other financial pressures. As a result, we expect our customers to continue to be cautious about their overall capital spending.” · word for word

China Reimbursement Pressure

“We cannot assure you that the rollout of the NHSA unified national framework or future actions by provincial or national healthcare agencies will not result in further pricing limits or pressures, which could have a material impact on procedure volumes and our instruments and accessories revenue in China.” · word for word

Supply Chain Disruption

“Restrictions on the export of rare earth elements, including magnets, and critical minerals from China could potentially restrict access to components used in many of our products and could have a material adverse effect on our business, financial condition, or results of operations.” · word for word

Tariff impact on gross margins; estimated 1.0% of revenue headwind in FY2026

“Non-GAAP gross profit margin to be within a range of 68.0% to 69.0% of revenue in 2026. This range includes an estimated impact from tariffs of 1.0% of revenue.” · word for word

Potential for additional tariffs beyond current expectations could materially impact financial results

“The estimated impact from tariffs, including the potential for material adverse impact on the Company’s financial results if additional tariffs beyond the Company’s current expectations are implemented” · word for word

Tariff cost pressure

“During the three months ended March 31, 2026, tariffs and other trade measures recognized in total cost of revenue were approximately $28 million.” · word for word

China regulatory and competitive headwinds

“In the first quarter of 2026, the competitive dynamics in China, various measures related to industrial policy, and the effects of this campaign contributed to fewer systems being placed in China than we anticipated.” · word for word

Hospital capital spending caution

“We continue to see some customers challenged by lower public funding of healthcare in certain geographic markets and other financial pressures. As a result, we expect our customers to continue to be cautious about their overall capital spending.” · word for word

Tariff impact estimated at 1% of revenue for FY2026, which could pressure gross margins.

“Non-GAAP gross profit margin range includes an estimated impact from tariffs of 1.0% of revenue.”

Share repurchase activity ($1.1B in Q1) reduces cash reserves; cash decreased $1.05B during the quarter.

“Cash, cash equivalents, and investments decreased $1.05B during the quarter, primarily driven by repurchases and acquisition.”

Ion System Placement Decline

“Ion system placements decreased 28% to 195.”

U.S. Bariatric Procedure Decline

“The number of U.S. da Vinci bariatric procedures performed declined in the high-single digits in 2025 compared to 2024.” · word for word

Competitive Pressure

“We face competition from several companies that have introduced or are developing new approaches and MIS products.”

Regulatory Compliance Cost

“Our products and operations are subject to regulation in the U.S. by the FDA and the State of California as well as by other countries and regions.” · word for word

Supply Chain Dependency

“Some of the components necessary for the assembly of our products are currently provided to us by sole-sourced suppliers.” · word for word

Tariff risk: 2026 gross margin guidance includes estimated 1.2% adverse impact from tariffs currently in effect; additional tariffs could further pressure margins.

“This range includes an estimated impact from tariffs of 1.2% of revenue, plus or minus 10 basis points. Should additional tariffs be implemented or existing tariffs be modified, the additional impact on the Company’s financial results in 2026” · word for word

Procedure growth deceleration: 2026 procedure growth guidance of 13-15% implies deceleration from 18% in 2025, indicating potential market maturation or competitive pressure.

“Worldwide da Vinci procedure growth of approximately 13% to 15% in 2026, compared to 18% in 2025” · word for word

Asia system placements declined 8% QoQ and 16% FY, indicating regional headwinds

“Asia system placements 88 in Q4 2025 vs 96 in Q4 2024, -8%; FY 269 vs 321, -16%”

Ion system placements declined 39% QoQ and 28% FY, suggesting slower adoption

“Ion System Placements 42 in Q4 2025 vs 69 in Q4 2024, -39%”

Minimal risk; role change likely reflects strategic refocus on AI.

“Dr. Miller will no longer be reporting directly to the Company’s Chief Executive Officer.” · word for word